Neuphoria Therapeutics (NEUP) Equity Average (2022 - 2025)
Neuphoria Therapeutics (NEUP) has disclosed Equity Average for 4 consecutive years, with $21.1 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 36.97% to $21.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.1 million through Dec 2025, up 36.97% year-over-year, with the annual reading at $31.5 million for FY2023, N/A changed from the prior year.
- Equity Average for Q4 2025 was $21.1 million at Neuphoria Therapeutics, up from $15.8 million in the prior quarter.
- The five-year high for Equity Average was $31.5 million in Q2 2023, with the low at $15.4 million in Q4 2024.
- Average Equity Average over 4 years is $21.3 million, with a median of $20.5 million recorded in 2025.
- Peak annual rise in Equity Average hit 36.97% in 2025, while the deepest fall reached 19.66% in 2025.
- Over 4 years, Equity Average stood at $24.5 million in 2022, then increased by 28.21% to $31.5 million in 2023, then plummeted by 51.02% to $15.4 million in 2024, then soared by 36.97% to $21.1 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at $21.1 million, $15.8 million, and $22.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.